Clinical trial · Interventional
S9624 Ifosfamide in Treating Patients With Meningeal Tumors
S9624: Phase II Study of Ifosfamide in Patients With Aggressive Meningeal Tumors
NCT00003292CI-TRIAL-00012605terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): lack of accrual
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ifosfamide in treating patients with meningeal tumors that have recurred or that cannot be removed surgically.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adult Brain Malignant Hemangiopericytoma | — | UNRESOLVED | — |
| Adult Fibrosarcoma | Adult Fibrosarcoma | ONTOLOGY_EXACT | 0.98 |
| Adult Leiomyosarcoma | Adult Leiomyosarcoma | ONTOLOGY_EXACT | 0.98 |
| Adult Malignant Meningioma | Adult Anaplastic (Malignant) Meningioma | ALIAS | 0.90 |
| Adult Rhabdomyosarcoma | Adult Rhabdomyosarcoma | ONTOLOGY_EXACT | 0.98 |
| Chondrosarcoma | Chondrosarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ifosfamide | Drug | Ifosfamide | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- ifosfamide
- description
- ifosfamide
- interventionNames
- Drug: ifosfamide
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically proven recurrent or unresectable: * Malignant meningioma * Intracranial hemangiopericytoma * Primary central nervous system sarcoma, including: * Fibrosarcoma * Rhabdomyosarcoma * Chondrosarcoma * Leiomyosarcoma * Measurable or evaluable disease on CT or MRI scan * Persistent disease following biopsy or incomplete resection OR * Recurrent disease following complete resection * No benign meningioma * No prior or current systemic sarcoma PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * SWOG 0-2 Life expectancy: * Not specified Hematopoietic: * WBC at least 3,000/mm\^3 * Absolute granulocyte count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Not specified Renal: * Creatinine no greater than 2.0 mg/dL Cardiovascular: * No myocardial infarction within the past 3 months * No active angina * No unstable heart rhythms * No congestive heart failure Other: * HIV negative * No allergy to study drugs * No serious concurrent medical or psychiatric illness * No uncontrolled peptic ulcer disease * No prior malignancy within past 5 years except adequately treated: * Basal or squamous cell carcinoma of the skin * Carcinoma in situ of the cervix * Not pregnant or nursing * Effective contraception required of fertile patients PRIOR CONCURRENT THERAPY: * Recovered from toxic effects of prior therapy and/or from postoperative complications Biologic therapy: * Not specified Chemotherapy: * No prior ifosfamide * No other concurrent chemotherapy Endocrine therapy: * No concurrent hormonal therapy (except estrogen replacement therapy) * Corticosteroids allowed if dose is stable or decreasing Radiotherapy: * At least 4 weeks since prior radiotherapy * Progressive disease following radiation required * No concurrent radiotherapy Surgery: * See Disease Characteristics
References
Publications (0)
Data not yet available
No reference posted for this study.